Treatment of Systemic Mastocytosis

Immunology and Allergy Clinics of North America

Volumn 26, Issue 3, 2006, Pages 549-573

  Wilson, Todd M ^a   Metcalfe, Dean D ^a   Robyn, Jamie ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; [4 [2 CYCLOPENTYL 9 (3 HYDROXYPHENETHYL)PURIN 6 YLAMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE; ACETYLSALICYLIC ACID; ADRENALIN; ALPHA INTERFERON; AP 23848; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CETIRIZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; CLADRIBINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DASATINIB; DIPHENHYDRAMINE; DOPAMINE; FEXOFENADINE; GLUCOCORTICOID; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; IMATINIB; IMD 0354; KETOTIFEN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LORATADINE; METHOXSALEN; MIDOSTAURIN; NARCOTIC ANALGESIC AGENT; NILOTINIB; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PREDNISONE; PROTON PUMP INHIBITOR; RANITIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D;

ABDOMINAL CRAMP; ANAPHYLAXIS; ANOREXIA; ASCITES; BLOOD CLOTTING DISORDER; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; BONE PAIN; CATARACT; CLINICAL TRIAL; COUNSELING; CYTOPENIA; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DRUG FATALITY; DRUG HYPERSENSITIVITY; FATIGUE; FEVER; GASTROESOPHAGEAL REFLUX; HUMAN; HYPOTENSION; HYPOTHYROIDISM; MALABSORPTION; MAST CELL; MAST CELL DEGRANULATION; MYALGIA; NONHUMAN; OPPORTUNISTIC INFECTION; OSTEOPENIA; OSTEOPOROSIS; PANCYTOPENIA; PEPTIC ULCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; REVIEW; SEDATION; SIDE EFFECT; SKIN CANCER; SPLENECTOMY; SPLENOMEGALY; SYSTEMIC MASTOCYTOSIS; TACHYCARDIA; URTICARIA PIGMENTOSA;

ANTINEOPLASTIC AGENTS; COUNSELING; HUMANS; INFLAMMATION MEDIATORS; MASTOCYTOSIS, SYSTEMIC; PATIENT EDUCATION; PATIENT EDUCATION AS TOPIC;

EID: 33747375668     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.iac.2006.05.009     Document Type: Review

References (161)

1. Escribano L., Akin C., Castells M., et al. Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol 81 12 (2002) 677-690
2. Lerno G., Slaats G., Coenen E., et al. Anaesthetic management of systemic mastocytosis. Br J Anaesth 65 2 (1990) 254-257
3. Goins V.A. Mastocytosis. Perioperative considerations. AORN J 54 6 (1991) 1227-1238
4. Metcalfe D.D. The treatment of mastocytosis: an overview. J Invest Dermatol 96 3 Suppl (1991) 55S-6S [discussion: 56S-9S]
5. Longley J., Duffy T.P., and Kohn S. The mast cell and mast cell disease. J Am Acad Dermatol 32 4 (1995) 545-561 [quiz: 562-4]
6. Oude Elberink J.N., de Monchy J.G., Kors J.W., et al. Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. J Allergy Clin Immunol 99 1 Pt 1 (1997) 153-154
7. Fricker S.P., Slade E., and Powell N.A. Effect of superoxide dismutase on nitric oxide production by RAW264 macrophages. Biochem Soc Trans 23 2 Suppl (1995) 231S
8. Alto W.A., and Clarcq L. Cutaneous and systemic manifestations of mastocytosis. Am Fam Physician 59 11 (1999) 3047-3054 3059-60
9. Teuber S.S., and Vogt P.J. An unproven technique with potentially fatal outcome: provocation/neutralization in a patient with systemic mastocytosis. Ann Allergy Asthma Immunol 82 1 (1999) 61-65
10. Marone G., and Stellato C. Activation of human mast cells and basophils by general anaesthetic drugs. Monogr Allergy 30 (1992) 54
11. Stellato C., and Marone G. Mast cells and basophils in adverse reactions to drugs used during general anesthesia. Chem Immunol 62 (1995) 108
12. Stellato C de P.A., Cirillo R., Mastronardi P., et al. Heterogeneity of human mast cells and basophils in response to muscle relaxants. Anesthesiology 74 6 (1991) 1078
13. Coleman M.A., Liberthson R.R., Crone R.K., et al. General anesthesia in a child with urticaria pigmentosa. Anesth Analg 59 9 (1980) 704
14. Scott Jr. H.W., Parris W.C., Sandidge P.C., et al. Hazards in operative management of patients with systemic mastocytosis. Ann Surg 197 5 (1983) 507
15. Greenblatt E.P., and Chen L. Urticaria pigmentosa: an anesthetic challenge. J Clin Anesth 2 2 (1990) 108
16. Vaughan S.T., and Jones G.N. Systemic mastocytosis presenting as profound cardiovascular collapse during anaesthesia. Anaesthesia 53 8 (1998) 804
17. Borgeat A., and Ruetsch Y.A. Anesthesia in a patient with malignant systemic mastocytosis using a total intravenous anesthetic technique. Anesth Analg 86 2 (1998) 442
18. Turk J., Oates J.A., and Roberts II L.J. Intervention with epinephrine in hypotension associated with mastocytosis. J Allergy Clin Immunol 71 2 (1983) 189-192
19. Fisher M.M., and Baldo B.A. Mast cell tryptase in anaesthetic anaphylactoid reactions. Br J Anaesth 80 1 (1998) 26
20. Engler R.J., and Davis W.S. Rush Hymenoptera venom immunotherapy: successful treatment in a patient with systemic mast cell disease. J Allergy Clin Immunol 94 3 Pt 1 (1994) 556-559
21. D'Inca M., Ghirarduzzi A., Albertini G., et al. [Systemic mastocytosis: a review of the literature and of the cases in Reggio Emilia from 1986 to 1994.]. Ann Ital Med Int 11 1 (1996) 52-58 [in Italian]
22. Worobec A.S. Treatment of systemic mast cell disorders. Hematol Oncol Clin North Am 14 3 (2000) 659-687
23. Austen K.F. Systemic mastocytosis. N Engl J Med 326 9 (1992) 639-640
24. Castells M., and Austen K.F. Mastocytosis: mediator-related signs and symptoms. Int Arch Allergy Immunol 127 2 (2002) 147
25. Prussin C., and Metcalfe D.D. 4. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 111 2 Suppl (2003) S486
26. Worobec A.S., and Metcalfe D.D. Mastocytosis: current treatment concepts. Int Arch Allergy Immunol 127 2 (2002) 153-155
27. Marone G., Spadaro G., Granata F., et al. Treatment of mastocytosis: pharmacologic basis and current concepts. Leuk Res 25 7 (2001) 583-594
28. Bianchine P., and Metcalfe D. Systemic mastocytosis. In: Kaplan A.P. (Ed). Allergy (1997), WB Saunders, Philadelphia 854-860
29. Metcalfe D. Clinical advances in mastocytosis: an interdisciplinary roundtable discussion. J Invest Dermatol 96 Suppl (1991) 1S-65S
30. Gasior-Chrzan B., and Falk E.S. Systemic mastocytosis treated with histamine H1 and H2 receptor antagonists. Dermatology 184 2 (1992) 149-152
31. Fenske N.A., Lober C.W., and Pautler S.E. Congenital bullous urticaria pigmentosa. Treatment with concomitant use of H1- and H2-receptor antagonists. Arch Dermatol 121 1 (1985) 115-118
32. Kurosawa M., Amano H., Kanbe N., et al. Heterogeneity of mast cells in mastocytosis and inhibitory effect of ketotifen and ranitidine on indolent systemic mastocytosis. J Allergy Clin Immunol 100 6 Pt 2 (1997) S25-S32
33. Frieri M., Alling D.W., and Metcalfe D.D. Comparison of the therapeutic efficacy of cromolyn sodium with that of combined chlorpheniramine and cimetidine in systemic mastocytosis. Results of a double-blind clinical trial. Am J Med 78 1 (1985) 9-14
34. Berg M.J., Bernhard H., and Schentag J.J. Cimetidine in systemic mastocytosis. Drug Intell Clin Pharm 15 3 (1981) 180-183
35. Hirschowitz B.I., and Groarke J.F. Effect of cimetidine on gastric hypersecretion and diarrhea in systemic mastocytosis. Ann Intern Med 90 5 (1979) 769-771
36. Johnson G.J., Silvis S.E., Roitman B., et al. Long-term treatment of systemic mastocytosis with histamine H2 receptor antagonists. Am J Gastroenterol 74 6 (1980) 485-489
37. Jensen R.T. Gastrointestinal abnormalities and involvement in systemic mastocytosis. Hematol Oncol Clin North Am 14 3 (2000) 579-623
38. Bredfeldt J.E., O'Laughlin J.C., Durham J.B., et al. Malabsorption and gastric hyperacidity in systemic mastocytosis. Results of cimetidine therapy. Am J Gastroenterol 74 2 (1980) 133-137
39. Achord J.L., and Langford H. The effect of cimetidine and propantheline on the symptoms of a patient with systemic mastocytosis. Am J Med 69 4 (1980) 610
40. Alexander R.R. Disodium cromoglycate in the treatment of systemic mastocytosis involving only bone 4. Acta Haematol 74 2 (1985) 108
41. Horan R.F., Sheffer A.L., and Austen K.F. Cromolyn sodium in the management of systemic mastocytosis. J Allergy Clin Immunol 85 5 (1990) 852-855
42. Soter N.A., Austen K.F., and Wasserman S.I. Oral disodium cromoglycate in the treatment of systemic mastocytosis. N Engl J Med 301 9 (1979) 465-469
43. Gruchalla R.S. Southwestern Internal Medicine Conference: mastocytosis: developments during the past decade. Am J Med Sci 309 6 (1995) 328-338
44. Businco L., Cantani A., Businco E., et al. Systemic mastocytosis in a 5-year-old child: successful treatment with disodium cromoglycate. Clin Allergy 14 2 (1984) 147-152
45. Czarnetzki B.M., and Behrendt H. Urticaria pigmentosa: clinical picture and response to oral disodium cromoglycate. Br J Dermatol 105 5 (1981) 563-567
46. Kettelhut B.V., and Metcalfe D.D. Pediatric mastocytosis. Ann Allergy 73 3 (1994) 197-202 [quiz: 202-7]
47. Kettelhut B.V., and Metcalfe D.D. Pediatric mastocytosis. J Invest Dermatol 96 3 Suppl (1991) 15S-8S
48. Haustein U.F., and Bedri M. [Bullous mastocytosis in a child.]. Hautarzt 48 2 (1997) 127-129 [in German]
49. Welch E.A., Alper J.C., Bogaars H., et al. Treatment of bullous mastocytosis with disodium cromoglycate. J Am Acad Dermatol 9 3 (1983) 349-353
50. Leaf F.A., Jaecks E.P., and Rodriguez D.R. Bullous urticaria pigmentosa. Cutis 58 5 (1996) 358-360
51. Reisberg I.R., and Oyakawa S. Mastocytosis with malabsorption, myelofibrosis, and massive ascites. Am J Gastroenterol 82 1 (1987) 54-60
52. Genovese A., Spadaro G., Triggiani M., et al. Clinical advances in mastocytosis. Int J Clin Lab Res 25 4 (1995) 178-188
53. Marone G., Spadaro G., and Genovese A. Biology, diagnosis and therapy of mastocytosis. Chem Immunol 62 (1995) 1-21
54. Bonnet P., Smadja C., Szekely A.M., et al. Intractable ascites in systemic mastocytosis treated by portal diversion. Dig Dis Sci 32 2 (1987) 209-213
55. Fonga-Djimi H.S., Gottrand F., Bonnevalle M., et al. A fatal case of portal hypertension complicating systemic mastocytosis in an adolescent. Eur J Pediatr 154 10 (1995) 819-821
56. Finotto S., Mekori Y.A., and Metcalfe D.D. Glucocorticoids decrease tissue mast cell number by reducing the production of the c-kit ligand, stem cell factor, by resident cells: in vitro and in vivo evidence in murine systems. J Clin Invest 99 7 (1997) 1721
57. Barton J., Lavker R.M., Schechter N.M., et al. Treatment of urticaria pigmentosa with corticosteroids. Arch Dermatol 121 12 (1985) 1516-1523
58. Lavker R.M., and Schechter N.M. Cutaneous mast cell depletion results from topical corticosteroid usage. J Immunol 135 4 (1985) 2368-2373
59. Guzzo C., Lavker R., Roberts II L.J., et al. Urticaria pigmentosa. Systemic evaluation and successful treatment with topical steroids. Arch Dermatol 127 2 (1991) 191-196
60. Johnstone P.A., Mican J.M., Metcalfe D.D., et al. Radiotherapy of refractory bone pain due to systemic mast cell disease. Am J Clin Oncol 17 4 (1994) 328
61. Marshall A., Kavanagh R.T., and Crisp A.J. The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis. Br J Rheumatol 36 3 (1997) 393-396
62. Cundy T., Beneton M.N., Darby A.J., et al. Osteopenia in systemic mastocytosis: natural history and responses to treatment with inhibitors of bone resorption. Bone 8 3 (1987) 149-155
63. Janjan N.A., Conway P., Lundberg J., et al. Radiation therapy in a case of systemic mastocytosis: evaluation of histamine levels and mucosal effects. Am J Clin Oncol 15 4 (1992) 337-339
64. Mackey S., Pride H.B., and Tyler W.B. Diffuse cutaneous mastocytosis. Treatment with oral psoralen plus UVA. Arch Dermatol 132 12 (1996) 1429-1430
65. Godt O., Proksch E., Streit V., et al. Short- and long-term effectiveness of oral and bath PUVA therapy in urticaria pigmentosa and systemic mastocytosis. Dermatology 195 1 (1997) 35-39
66. Christophers E., Honigsmann H., Wolff K., et al. PUVA-treatment of urticaria pigmentosa. Br J Dermatol 98 6 (1978) 701-702
67. Czarnetzki B.M., Rosenbach T., Kolde G., et al. Phototherapy of urticaria pigmentosa: clinical response and changes of cutaneous reactivity, histamine and chemotactic leukotrienes. Arch Dermatol Res 277 2 (1985) 105-113
68. Kolde G., Frosch P.J., and Czarnetzki B.M. Response of cutaneous mast cells to PUVA in patients with urticaria pigmentosa: histomorphometric, ultrastructural, and biochemical investigations. J Invest Dermatol 83 3 (1984) 175-178
69. Smith M.L., Orton P.W., Chu H., et al. Photochemotherapy of dominant, diffuse, cutaneous mastocytosis. Pediatr Dermatol 7 4 (1990) 251-255
70. Stege H., Schopf E., Ruzicka T., et al. High-dose UVA1 for urticaria pigmentosa. Lancet 347 8993 (1996) 64
71. Vella Briffa D., Eady R.A., James M.P., et al. Photochemotherapy (PUVA) in the treatment of urticaria pigmentosa. Br J Dermatol 109 1 (1983) 67-75
72. Metcalfe D. Middleton's allergy: principles and practice; mastocytosis syndromes, vol. 2. 6th edition (2003), Mosby, Philadelphia
73. Abdullah A.N., and Keczkes K. Cutaneous and ocular side-effects of PUVA photochemotherapy-a 10-year follow-up study. Clin Exp Dermatol 14 6 (1989) 421-424
74. Gobello T., Mazzanti C., Sordi D., et al. Medium- versus high-dose ultraviolet A1 therapy for urticaria pigmentosa: a pilot study. J Am Acad Dermatol 49 4 (2003) 679-684
75. Poterack C.D., Sheth K.J., Henry D.P., et al. Shock in an infant with bullous mastocytosis. Pediatr Dermatol 6 2 (1989) 122-125
76. Walton J. Mastocytosis/vasodilatory shock in a 25-year-old woman. J Emerg Nurs 15 4 (1989) 356-357
77. Horan R.F., and Austen K.F. Systemic mastocytosis: retrospective review of a decade's clinical experience at the Brigham and Women's Hospital. J Invest Dermatol 96 3 Suppl (1991) 5S-13S [discussion: 13S-4S]
78. Gonera R.K., Oranje W.A., and Wolffenbuttel B.H. Shock of unknown origin-think of mastocytosis. Neth J Med 50 4 (1997) 165
79. Desborough J.P., Taylor I., Hattersley A., et al. Massive histamine release in a patient with systemic mastocytosis. Br J Anaesth 65 6 (1990) 833-836
80. Worobec A., and Metcalfe D.D. Current therapy in allergy, immunology and rheumatology (1996), Mosby, St. Louis (MO)
81. Crawhall J.C., and Wilkinson R.D. Systemic mastocytosis: management of an unusual case with histamine (H1 and H2) antagonists and cyclooxygenase inhibition. Clin Invest Med 10 1 (1987) 1-4
82. Butterfield J.H., Kao P.C., Klee G.C., et al. Aspirin idiosyncrasy in systemic mast cell disease: a new look at mediator release during aspirin desensitization. Mayo Clin Proc 70 5 (1995) 481-487
83. Valent P., Akin C., Sperr W.R., et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res 27 7 (2003) 635-641
84. Valent P., Akin C., Sperr W.R., et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 122 5 (2003) 695
85. Valent P., Akin C., Sperr W.R., et al. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma 46 1 (2005) 35-48
86. Clemens M.J. Interferons and apoptosis. J Interferon Cytokine Res 23 6 (2003) 277
87. Bonifazi F., de Viro A., Rosti G., et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 98 10 (2001) 3074-3081
88. Hehlmann R., Heimpel H., Hasford J., et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 84 12 (1994) 4064
89. Ohnishi K., Ohno R., Tomonaga M., et al. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 86 3 (1995) 906
90. Ohnishi K., Tomonaga M., Kamada N., et al. A long term follow-up of a randomized trial comparing interferon-alpha with busulfan for chronic myelogenous leukemia. The Kouseisho Leukemia Study Group. Leuk Res 22 9 (1998) 779
91. Kluin-Nelemans H.C., Jansen J.H., Breukelman H., et al. Response to interferon alfa-2b in a patient with systemic mastocytosis. N Engl J Med 326 9 (1992) 619-623
92. Butterfield J.H. Response of severe systemic mastocytosis to interferon alpha. Br J Dermatol 138 3 (1998) 489-495
93. Czarnetzki B.M., Algermissen B., Jeep S., et al. Interferon treatment of patients with chronic urticaria and mastocytosis. J Am Acad Dermatol 30 3 (1994) 500-501
94. Fiehn C., Prummer O., Gallati H., et al. Treatment of systemic mastocytosis with interferon-gamma: failure after appearance of anti-IFN-gamma antibodies. Eur J Clin Invest 25 8 (1995) 615-618
95. Hennessy B., Giles F., Cortes J., et al. Management of patients with systemic mastocytosis: review of M.D. Anderson Cancer Center experience. Am J Hematol 77 3 (2004) 209-214
96. Hubner C., Wedding U., Strater J., et al. Clinical stable systemic mastocytosis with interferon alpha-2b therapy. J Intern Med 241 6 (1997) 529-533
97. Lehmann T., and Lammle B. IFNalpha treatment in systemic mastocytosis. Ann Hematol 78 10 (1999) 483-484
98. Pulik M., Lionnet F., Petit A., et al. Long-term response to interferon-alpha in a patient with systemic mastocytosis and chronic myelomonocytic leukemia. Am J Hematol 47 1 (1994) 66
99. Simon J., Lortholary O., Caillat-Vigneron N., et al. Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature. Pathol Biol (Paris) 52 5 (2004) 294-299
100. Weide R., Ehlenz K., Lorenz W., et al. Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b. Ann Hematol 72 1 (1996) 41-43
101. Worobec A.S., Kirshenbaum A.S., Schwartz L.B., et al. Treatment of three patients with systemic mastocytosis with interferon alpha-2b. Leuk Lymphoma 22 5-6 (1996) 501-508
102. Petit A., Pulik M., Gaulier A., et al. Systemic mastocytosis associated with chronic myelomonocytic leukemia: clinical features and response to interferon alfa therapy. J Am Acad Dermatol 32 5 Pt 2 (1995) 850-853
103. Kolde G., Sunderkotter C., and Luger T.A. Treatment of urticaria pigmentosa using interferon alpha. Br J Dermatol 133 1 (1995) 91-94
104. Hauswirth A.W., Simonitsch-Klupp I., Uffmann M., et al. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res 28 3 (2004) 249-257
105. Goodman G.R., Beutler E., and Saven A. Cladribine in the treatment of hairy-cell leukaemia. Best Pract Res Clin Haematol 16 1 (2003) 101
106. Carrera C.J., Terai C., Lotz M., et al. Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy. J Clin Invest 86 5 (1990) 1480-1488
107. Kirshenbaum A.S., Goff J.P., Semere T., et al. Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). Blood 94 7 (1999) 2333
108. Tefferi A., Li C.Y., Butterfield J.H., et al. Treatment of systemic mast-cell disease with cladribine. N Engl J Med 344 4 (2001) 307-309
109. Escribano L., Perez de Oteyza J., Nunez R., et al. Cladribine induces immunophenotypical changes in bone marrow mast cells from mastocytosis. Report of a case of mastocytosis associated with a lymphoplasmacytic lymphoma. Leuk Res 26 11 (2002) 1043-1046
110. Kluin-Nelemans H.C., Oldhoff J.M., Van Doormaal J.J., et al. Cladribine therapy for systemic mastocytosis. Blood 102 13 (2003) 4270-4276
111. Pardanani A., Hoffbrand A.V., Butterfield J.H., et al. Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. Leuk Res 28 2 (2004) 127-131
112. Penack O., Sotlar K., Noack F., et al. Cladribine therapy in a patient with an aleukemic subvariant of mast cell leukemia. Ann Hematol 84 10 (2005) 692-693
113. Druker B.J. Imatinib as a paradigm of targeted therapies. Adv Cancer Res 91 (2004) 1-30
114. Bono P., Krause A., von Mehren M., et al. Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib. Blood 103 8 (2004) 2929-2935
115. Cools J., Stover E.H., Wlodarska I., et al. The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia. Curr Opin Hematol 11 1 (2004) 51-57
116. Duensing A., Heinrich M.C., Fletcher C.D., et al. Biology of gastrointestinal stromal tumors: KIT mutations and beyond. Cancer Invest 22 1 (2004) 106-116
117. Klion A.D., Noel P., Akin C., et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 101 12 (2003) 4660
118. Klion A.D., Robyn J., Akin C., et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 103 2 (2004) 473
119. Akin C., Brockow K., D'Ambrosio C., et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 31 8 (2003) 686-692
120. Ma Y., Zeng S., Metcalfe D.D., et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99 5 (2002) 1741-1744
121. Zermati Y., De Sepulveda P., Feger F., et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 22 5 (2003) 660-664
122. Frost M.J., Ferrao P.T., Hughes T.P., et al. Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 1 12 (2002) 1115-1124
123. Musto P., Falcone A., Sanpaolo G., et al. Inefficacy of imatinib-mesylate in sporadic, aggressive systemic mastocytosis. Leuk Res 28 4 (2004) 421
124. Pardanani A., Elliott M., Reeder T., et al. Imatinib for systemic mast-cell disease. Lancet 362 9383 (2003) 535
125. Pardanani A., Ketterling R.P., Brockman S.R., et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 102 9 (2003) 3093
126. Akin C., Fumo G., Yavuz A.S., et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 103 8 (2004) 3222
127. Travis W.D., Li C.Y., Hoagland H.C., et al. Mast cell leukemia: report of a case and review of the literature. Mayo Clin Proc 61 12 (1986) 957-966
128. Valent P., Horny H.P., Li C.Y., et al. Mastocytosis. World Health Organization classification of tumours: pathology and genetics: tumours of haematopoietic and lymphoid tissues (2001), IARC Press, Lyon (France) p. 291
129. Friedman B., Darling G., Norton J., et al. Splenectomy in the management of systemic mast cell disease. Surgery 107 1 (1990) 94
130. Grundfest S., Cooperman A.M., Ferguson R., et al. Portal hypertension associated with systemic mastocytosis and splenomegaly. Gastroenterology 78 2 (1980) 370
131. Smith G.B., Gusberg R.J., Jordan R.H., et al. Histamine levels and cardiovascular responses during splenectomy and splenorenal shunt formation in a patient with systemic mastocytosis. Anaesthesia 42 8 (1987) 861
132. Fodinger M., Fritsch G., Winkler K., et al. Origin of human mast cells: development from transplanted hematopoietic stem cells after allogeneic bone marrow transplantation. Blood 84 9 (1994) 2954-2959
133. Przepiorka D., Giralt S., Khouri I., et al. Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases. Am J Hematol 57 1 (1998) 24
134. Ronnov-Jessen D., Lovgreen N.P., and Horn T. Persistence of systemic mastocytosis after allogeneic bone marrow transplantation in spite of complete remission of the associated myelodysplastic syndrome. Bone Marrow Transplant 8 5 (1991) 413
135. Spyridonidis A., Thomas A.K., Bertz H., et al. Evidence for a graft-versus-mast-cell effect after allogeneic bone marrow transplantation. Bone Marrow Transplant 34 6 (2004) 515
136. Barrett A.J., and Malkovska V. Graft-versus-leukaemia: understanding and using the alloimmune response to treat haematological malignancies. Br J Haematol 93 4 (1996) 754-761
137. Barrett A.J., and van Rhee F. Graft-versus-leukaemia. Baillieres Clin Haematol 10 2 (1997) 337-355
138. Barrett A.J. Mechanisms of the graft-versus-leukemia reaction. Stem Cells 15 4 (1997) 248-258
139. Barrett J., and Childs R. Non-myeloablative stem cell transplants. Br J Haematol 111 1 (2000) 6-17
140. Nakamura R., Chakrabarti S., Akin C., et al. A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. Bone Marrow Transplant 37 4 (2006) 353-358
141. Growney J.D., Clark J.J., Adelsperger J., et al. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 106 2 (2005) 721-724
142. Gotlib J., Berube C., Growney J.D., et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 106 8 (2005) 2865-2870
143. O'Hare T., Walters D.K., Deininger M.W., et al. AMN107: tightening the grip of imatinib. Cancer Cells 7 2 (2005) 117
144. von Bubnoff N., Gorantla S.H., Kancha R.K., et al. The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107. Leukemia 19 9 (2005) 1670-1671
145. Giles F., Kantarjian H., Wassmann B., et al. A phase I/II study of AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, on a continuous daily dosing schedule in adult patients with imatinib-resistant advanced phase chronic myeloid leukemia (CML) or relapsed/refractory Philadelphia chromosome (Ph+) acute lymphocytic leukemia (ALL). Blood 104 (2004) 10a
146. Shah N.P., Tran C., Lee F.Y., et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. [abstract]. Blood (2004) 104
147. Sawyers C.L.S.N.P., Kantarjain H.M., Donato N., et al. Hematologic and cytogenetic responses in imatinib-resistant chronic phase chronic myeloid leukemia patients treated with the dual SRC//ABL kinase inhibitor. Blood 104 11 (2004) 1a
148. Shah N.P., Lee F.Y., Luo R., et al. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in the majority of patients with systemic mastocytosis. Blood 108 1 (2006) 286-291
149. Schittenhelm M.M., Shiraga S., Schroeder A., et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 66 1 (2006) 473-481
150. Corbin A.S., Griswold I.J., La R.P., et al. Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970. Blood 104 12 (2004) 3754
151. Griswold I.J., Shen L.J., La Rosee P., et al. Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis. Blood 104 9 (2004) 2912-2918
152. Corbin A.S., Demehri S., Griswold I.J., et al. In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit. Blood 106 1 (2005) 227-234
153. Fumo G., Akin C., Metcalfe D.D., et al. 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood 103 3 (2004) 1078-1084
154. Tanaka A., Konno M., Muto S., et al. A novel NF-κB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood 105 6 (2005) 2324-2331
155. Gleixner K.V., Mayerhofer M., Aichberger K.J., et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA), and evaluation of cooperative drug effects. Blood 107 2 (2006) 752-759
156. Butterfield J.H. Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis. Acta Haematol 114 1 (2005) 26-40
157. Schernthaner G.H., Spanblochl E., Sperr W.R., et al. Effects of interferon-alpha2b treatment on ex vivo differentiation of mast cells from circulating progenitor cells in a patient with systemic mastocytosis. Ann Hematol 79 12 (2000) 660
158. Casassus P., Caillat-Vigneron N., Martin A., et al. Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol 119 4 (2002) 1090-1097
159. Nieva J., and Saven A. Cladribine activity in systemic mast cell disease: application of biochemistry in the modern era of molecular biology. Leuk Res 28 2 (2004) 113-114
160. Heinrich M.C., Griffith D.J., Druker B.J., et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96 3 (2000) 925-932
161. Gotlib J., Berube C., Growney J.D., et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood (2005)